Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease

Incidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate cancer, two-thirds of which are novel targeted therapies or immunotherapies. Collectively, the nine drugs in late-phase development are forecast to achieve $2,780m in sales by 2018.

Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies

No therapeutic cancer vaccine has received approval in any of the seven major pharmaceutical markets, despite extensive research efforts. However, with one product in pre-registration in the US, the prospect of the first marketed therapeutic cancer vaccine in the seven major markets is now closer to reality.

Dendreon: landmark cancer vaccine approval but high costs may hinder uptake

Having been approved by the FDA in castration-resistant prostate cancer, Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market. This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used.

Affordable On-Demand software for regulatory affairs professionals

Hepatitis C - High unmet need drives rapid innovation

The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.

Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey

China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.

EASL 2010: promising developments in the hepatitis C pipeline

The limitations of the current standard of care for hepatitis C virus infection have left significant room for the development of novel agents, and consequently the pipeline is highly active. Data from studies investigating the use of these agents in hepatitis C-infected patients were a key focus point at this year's European Association of the Study of the Liver meeting.

The PHARM Connect Congress 2011

The PHARM Connect Congress 2011 offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe.

Global Ophthalmology Devices Market

Global ophthalmology devices and drugs market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. With the introduction of ophthalmic devices equipped with sophisticated technologies, people are increasingly opting for ophthalmic surgeries to correct their eye related disorders.

Second annual Pharmaceutical Risk-Sharing  & Value-based Pricing and Reimbursement Models

Bratislava, 15-16 th April 2010

Not being a specialist in the area of Risk-Sharing & Value-based Pricing this event was an excellent introduction for me. Meeting P&R experts from some of the most important pharma companies in the world as well as hearing their detailed presentations was a really good experience.

The event was splendidly organised by Next Level Pharma in Trend Hotel,Bratislava, SK, near the city centre, which was an excellent location. The overall impession was ruined only by a bad weather which did not allow a proper sightseeing of the city and disturbed air traffic which made problems to the return flight of most participants. 

Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist's new report, "Nonalcoholic Steatohepatitis (NASH) - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData's report, "HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders.

GlaxoSmithKline: H1N1 hype unfounded as UK caps vaccine order

The UK government has capped its order of the H1N1 vaccine from GlaxoSmithKline. Following poor uptake of the vaccine in several European markets, the UK Department of Health has opted to limit its H1N1 contract with GlaxoSmithKline to 34.8 million doses. Despite the media hype surrounding the influenza outbreak, the mild course of the pandemic and negative public opinion of the vaccine means that its commercial impact will be significantly reduced.

Diagnostic ECG Market (2009 - 2014)

The global diagnostic ECG market is categorized into three submarkets: the rest systems the stress systems and holter systems. These systems are used to measure the electrical activity of the heart. Amongst the three systems, rest system is the most widely-used diagnostic tool. The global market for rest system is expected to grow at a CARG of 9.6% from 2009 to 2014.

In-Vitro Diagnostics (IVD) Market in BRIC (2010 - 2014)

The IVD markets of BRIC economies offer immense growth opportunities due to the increasing healthcare budgets in these nations, along with the increasing number of private corporate hospitals, and the rising income levels backed by a huge, untapped population bases.

DIABETES III: A CAUSE OF ALZHEIMER’S DISEASE

INTRODUCTION

Type III diabetes also known as hybrid or double diabetes is a new and dangerous phenomenon. It is found that type III Diabetes affects brain insulin levels, and appears to be one of the major causes of Alzheimer's disease . Insulin receptors in the brain are sensitive to particles known as ADDL's.

Clinical Trials in Oncology

16th-17th September 2010, Budapest

Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide, with rising research, treatment and commercial importance. Carefully designed and efficiently conducted clinical trial can deliver new oncology drugs and diagnostics to the marketplace. There is a number of challenges in this area which remain; specifically regarding patient recruitment and regulatory issues.

6^th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

15th - 17th September 2010, Lisbon

What are the best practices to achieve QC Laboratory Excellence? How successful are you in adopting and sustaining consistent, harmonized & compliant quality systems? Leading Pharmaceutical companies will share their first hand experience with transforming the mindset of people, creating the culture of change and continuous improvement in both Quality and Operational Excellence.